Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Commercial Officer | September 11, 2026 | September 15, 2026 |
| aTYR PHARMA INCATYR · Entity 7233 | Director | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,297 |
Ending reported balance
After 2026-09-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-11 · Grant · Acquired 6,275 · Balance 70,683 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Row 2 · 2026-09-11 · Tax withholding · Disposed 3,386 · Balance 67,297 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
aTYR PHARMA INC
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-11 | Direct | 50,000 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Grant · Acquired 50,000 · Balance 50,000 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 3,386 | $156.22 | $528,960.92 |
DisclosureSEC source: 0001643653-26-000018 · wk-form4_1789506163.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,297 F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 6,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000018 · wk-form4_1789506163.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,683 F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 00:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 3,194 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001643653-26-000016 · wk-form4_1789086545.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,194 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. These options were due to expire on February 6, 2027. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 00:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,154 | $154.61 | $333,029.94 |
DisclosureSEC source: 0001643653-26-000016 · wk-form4_1789086545.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,408 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 00:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 3,194 | $43.24 | $138,108.56 |
DisclosureSEC source: 0001643653-26-000016 · wk-form4_1789086545.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 178 shares purchased on February 27, 2026 and August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:15 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001643653-26-000014 · ownership.xml · derivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-05-11 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 6,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · derivative · entry 13 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,365 Underlying: Common Stock · 6,365 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 36,287 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · derivative · entry 12 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,287 Underlying: Common Stock · 36,287 shares Expires 2036-02-13 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · derivative · entry 11 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,083 Underlying: Common Stock · 2,083 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · derivative · entry 10 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,924 Underlying: Common Stock · 1,961 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, vested as to 1,961 shares on February 13, 2026, and will vest as to 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, vested as to 1,961 shares on February 13, 2026, and will vest as to 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 8,963 | $124.12 | $1,112,487.56 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 8 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,190 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 16,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 7 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,153 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,124 | $124.12 | $139,510.88 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 6 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,540 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,058 | $124.12 | $131,318.96 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,581 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · derivative · entry 9 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,017 Underlying: Common Stock · 2,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,005 shares on February 12, 2026, and will vest as to 2,005 shares on February 12, 2027, 2,005 shares on February 12, 2028, and 2,005 shares on February 12, 2029, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,005 shares on February 12, 2026, and will vest as to 2,005 shares on February 12, 2027, 2,005 shares on February 12, 2028, and 2,005 shares on February 12, 2029, subject to the terms and conditions of the award. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,082 | $123.10 | $133,194.20 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,678 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000008 · wk-form4_1770160887.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and vested as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and vested as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,292 | $136.06 | $175,789.52 |
DisclosureSEC source: 0001643653-26-000008 · wk-form4_1770160887.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,755 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000008 · wk-form4_1770160887.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 22:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 5,970 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001643653-25-000007 · wk-form4_1764714101.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,860 Underlying: Common Stock · 5,970 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 22:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,970 | $151.74 | $905,880.64 |
DisclosureSEC source: 0001643653-25-000007 · wk-form4_1764714101.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,893 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.70 to $153.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 22:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,970 | $35.99 | $214,860.30 |
DisclosureSEC source: 0001643653-25-000007 · wk-form4_1764714101.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| November 28, 2025 Filed Jan 16, 2026 22:17 UTC Amendment | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 12,830 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001643653-26-000005 · wk-form4a_1768601876.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,830 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options. F4 · derivative.exercise_date: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026. Read SEC document |
| November 28, 2025 Filed Jan 16, 2026 22:17 UTC Amendment | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 12,830 | $35.99 | $461,751.70 |
DisclosureSEC source: 0001643653-26-000005 · wk-form4a_1768601876.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options. F2 · balance_after: Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| May 01, 2025 Filed May 2, 2025 21:18 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0000950170-25-062935 · ownership.xml · derivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-01 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 1, 2026 or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,961 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000057 · wk-form4_1739574214.xml · derivative · entry 8 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,885 Underlying: Common Stock · 1,961 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, and will vest as to 1,961 shares on February 13, 2026, 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award. F9 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, and will vest as to 1,961 shares on February 13, 2026, 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,083 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000057 · wk-form4_1739574214.xml · derivative · entry 7 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,166 Underlying: Common Stock · 2,083 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F8 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, and will vest as to 2,083 shares on February 13, 2026, and 2,083 shares on February 13, 2027, subject to the terms and conditions of the award. F8 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, and will vest as to 2,083 shares on February 13, 2026, and 2,083 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,056 | $116.71 | $123,244.81 |
DisclosureSEC source: 0000914475-25-000057 · wk-form4_1739574214.xml · nonDerivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,689 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.86 to $117.78. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,961 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000057 · wk-form4_1739574214.xml · nonDerivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,098 | $116.74 | $128,182.83 |
DisclosureSEC source: 0000914475-25-000057 · wk-form4_1739574214.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,784 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,083 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000057 · wk-form4_1739574214.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 8,022 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000057 · wk-form4_1739574214.xml · derivative · entry 6 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,022 Underlying: Common Stock · 8,022 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 42,805 | $0.00 Strike: $117.18 | $0.00 |
DisclosureSEC source: 0000914475-25-000057 · wk-form4_1739574214.xml · derivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,805 Underlying: Common Stock · 42,805 shares Expires 2035-02-12 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 23:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 980 | $118.31 | $115,940.37 |
DisclosureSEC source: 0000914475-25-000047 · wk-form4_1739403854.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,799 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.07 to $123.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 23:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,860 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000047 · wk-form4_1739403854.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,860 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 23:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,860 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000047 · wk-form4_1739403854.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000021 · wk-form4_1738708526.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,294 Underlying: Common Stock · 2,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and will vest as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and will vest as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,207 | $152.94 | $184,598.58 |
DisclosureSEC source: 0000914475-25-000021 · wk-form4_1738708526.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,919 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes an aggregate of 54 shares purchased on August 31, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000021 · wk-form4_1738708526.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 21:15 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-24-135798 · ownership.xml · derivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-12-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning January 10, 2025, such that this option will be fully exercisable on December 10, 2027, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 12,587 | $81.05 Strike: $81.05 | $1,020,176.35 |
DisclosureSEC source: 0000914475-24-000111 · wk-form4_1713388780.xml · derivative · entry 6 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,587 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 7, 2019 and vested in 48 equal monthly installments beginning March 7, 2019. These options will expire ten years from the date of grant on February 07, 2029. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 7,231 | $81.49 Strike: $81.49 | $589,254.19 |
DisclosureSEC source: 0000914475-24-000111 · wk-form4_1713388780.xml · derivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,292 Underlying: Common Stock · 7,231 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018. These options will expire ten years from the date of grant on February 05, 2028. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 12,587 | $133.36 | $1,678,660.22 |
DisclosureSEC source: 0000914475-24-000111 · wk-form4_1713388780.xml · nonDerivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,778 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.56 to $136.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 12,587 | $81.05 | $1,020,176.35 |
DisclosureSEC source: 0000914475-24-000111 · wk-form4_1713388780.xml · nonDerivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 7,231 | $133.36 | $964,359.42 |
DisclosureSEC source: 0000914475-24-000111 · wk-form4_1713388780.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,778 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.56 to $136.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 7,231 | $81.49 | $589,254.19 |
DisclosureSEC source: 0000914475-24-000111 · wk-form4_1713388780.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 21:33 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 69,521 | $81.05 Strike: $81.05 | $5,634,677.05 |
DisclosureSEC source: 0000914475-24-000096 · wk-form4_1710538413.xml · derivative · entry 6 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,587 Underlying: Common Stock · 69,521 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted February 7, 2019 and vested in 48 equal monthly installments beginning March 7, 2019. These options will expire ten years from the date of grant on February 07, 2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.